GMP Monitoring and Continuous Process Verification: Stage 3 of the FDA Process Validation Guidance

  • Richard K. Burdick
  • David J. LeBlond
  • Lori B. Pfahler
  • Jorge Quiroz
  • Leslie Sidor
  • Kimberly Vukovinsky
  • Lanju Zhang
Chapter
Part of the Statistics for Biology and Health book series (SBH)

Abstract

The FDA Process Validation Guidance (2011) advocates Continued process verification Procedure validation a life cycle approach to product manufacturing which ensures the process can reliably and consistently produce quality product that meets the therapy’s desired efficacy and safety profile. This life cycle approach emphasizes collection and evaluation of appropriate data as evidence to demonstrate that the process is in a controlled state to deliver quality product. It has three stages: Process design, process qualification, and continued process verification (CPV). In CPV stage, data are continuously collected and evaluated to verify the process remains in the desired controlled state. This chapter discusses the key components of CPV and statistical tools that are useful for this purpose.

Keywords

Acceptance quality level (AQL) Acceptance sampling Annual product review Continued process verification Corrective and preventative action (CAPA) Critical material attribute (CMaA) Critical method attribute (CMeA), Critical process parameter (CPP) Critical quality attribute (CQA) Lot tolerance percent defective (LTPD) Operating characteristic (OC) curve Out of specification (OOS) Process capability Statistical control charts 

References

  1. Alsmeyer D, Pazhayattil A (2014) A case for stage 3 continued process verification. Pharmaceutical Manufacturing. http://www.pharmamanufacturing.com/articles/2014/stage3-continued-process-verification/?show=all. Accessed 7 June 2016
  2. Altan S, Hare L, Strickland H (2016) Process capability and statistical process control. In: Zhang L (ed) Chapter 21 of nonclinical statistics for pharmaceutical and biotechnology industries. Springer, Heidelberg, pp 549–573CrossRefGoogle Scholar
  3. ASTM (2010) Manual on presentation of data and control chart analysis, 8th edn. Neubauer DV (ed), ASTM International, West ConshohockenGoogle Scholar
  4. ASTM E2281 (2015) Standard practice for process and measurement capability indices. ASTM International, West ConshohockenGoogle Scholar
  5. ASTM E2587 (2016) Standard practice for use of control charts in statistical process control. ASTM International, West ConshohockenGoogle Scholar
  6. BioPhorum Operations Group (2014) Continued process verification: an industry position paper with example plan. www.biophorum.com/Page/123/BPOG-CPV-Case-Study.htm. Accessed 7 June 2016Google Scholar
  7. Burdick R, Ye F (2016) Acceptance sampling. In: Zhang L (ed) Chapter 20 of nonclinical statistics for pharmaceutical and biotechnology industries. Springer, Heidelberg, pp 533–548CrossRefGoogle Scholar
  8. CMC Biotech Working Group (2009) A-Mab: a case study in bioprocess development, Version 2.1, http://c.ymcdn.com/sites/www.casss.org/resource/resmgr/imported/A-Mab_Case_Study_Version_2-1.pdf. Accessed 7 June 2016
  9. Food and Drug Administration. Center for Drugs Evaluation Research (2011) Process validation: general principles and practices, guidance for industryGoogle Scholar
  10. International Conference on Harmonization (ICH) (2005) Q9 Quality risk managementGoogle Scholar
  11. International Conference on Harmonization (ICH) (2008) Q10 Pharmaceutical quality systemGoogle Scholar
  12. International Conference on Harmonization (ICH) (2009) Q8 (R2) Pharmaceutical developmentGoogle Scholar
  13. Kiermeier A (2008) Visualizing and assessing acceptance sampling plans: the R package acceptancesampling. J Stat Software 26(6):1–20CrossRefGoogle Scholar
  14. Montgomery DC (2013) Introduction to statistical quality control, 7th edn. Wiley, New YorkMATHGoogle Scholar
  15. Nelson LS (1984) The Shewhart control chart-tests for special causes. J Qual Technol 16:237–239Google Scholar
  16. Schilling RG, Neubauer DV (2009) Acceptance sampling in quality control, 2nd edn. Chapman and Hall, LondonMATHGoogle Scholar
  17. Strickland H, Altan S (2016) In: Zhang L (ed) Chapter 19 of nonclinical statistics for pharmaceutical and biotechnology industries. Springer, Heidelberg, pp 501–531CrossRefGoogle Scholar
  18. Wheeler D J (2012) Understanding statistical process control (3rd Ed.). SPC Press KnoxvilleGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Richard K. Burdick
    • 1
  • David J. LeBlond
    • 2
  • Lori B. Pfahler
    • 3
  • Jorge Quiroz
    • 4
  • Leslie Sidor
    • 5
  • Kimberly Vukovinsky
    • 6
  • Lanju Zhang
    • 7
  1. 1.Elion LabsLouisvilleUSA
  2. 2.CMC StatisticsWadsworthUSA
  3. 3.Merck & Co., Inc.TelfordUSA
  4. 4.Merck & Co., Inc.KenilworthUSA
  5. 5.BiogenCambridgeUSA
  6. 6.PfizerOld SaybrookUSA
  7. 7.Nonclinical Statistics, Abbvie Inc.North ChicagoUSA

Personalised recommendations